Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

NCT04704921 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04704921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 29, 2020
Completion date
November 30, 2027
Enrollment
671 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

amd, choroidal neovascularization, cnv, namd, neovascular age-related macular degeneration, neovascular amd, wamd, wet age-related macular degeneration, wet amd